Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clone 3
- Development stage
- Preclinical
- Lead developer
- Adnexus Biotechnologies
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Clone 3 is a broadly neutralizing human monoclonal antibody (bnAb) developed by Adnexus Biotechnologies for the treatment and prevention of HIV/AIDS. Derived from a long-term non-progressor patient, the antibody targets the highly conserved KLIC epitope within the immunodominant cluster II region of the HIV-1 gp41 envelope protein. By binding to this conserved sequence, which is present in approximately 98% of viral strains worldwide, Clone 3 neutralizes primary HIV isolates and prevents viral entry into host cells. The candidate is being developed in both IgG and IgA formats to provide both systemic and mucosal protection. It is currently in the IND-enabling phase of development, with Samsung Biologics serving as the manufacturing partner for large-scale production.
- Other names
- Clone 3 AntibodyClone3 AntibodyClone-3 Antibodygp41 (KLIC epitope) monoclonal antibody
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on Clone 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clone 3.